IRIDEX Corporation — Q1 2024 Form 10-Q
Business and period: IRIDEX develops and sells ophthalmic laser systems, delivery devices, consumables, and related services for glaucoma and retinal conditions. This unaudited report covers the 13 weeks ended March 30, 2024; the comparable period ended April 1, 2023. Amounts below are in U.S. dollars.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $11.8 million | $13.7 million | Down 14.2% |
| Gross profit / margin | $4.5 million / 37.9% | $5.9 million / 43.3% | Profit down 25%; margin down 5.4 percentage points |
| Operating expenses | $7.8 million | $8.3 million | Down 6.4% |
| Operating loss | $3.3 million | $2.3 million | Loss widened |
| Net loss | $3.5 million; $0.21 per share | $2.1 million; $0.13 per share | Loss widened |
| Cash used in operations | $1.6 million | $2.8 million | Use decreased |
Revenue mix and drivers: Cyclo G6 revenue declined 19.5% to $3.0 million, Retina declined 6.1% to $6.8 million, and Other declined 27.9% to $2.0 million. Management attributed the overall decline to softer product demand and lower royalties following expiration of licensed patents. Topcon represented 32% of revenue, including $0.4 million of exclusive distribution-rights revenue.
Profitability: Management attributed lower gross margin primarily to reduced overhead absorption and a more favorable product mix in the prior-year quarter. Research and development fell 12.2% and sales and marketing fell 12.5%; general and administrative expense rose 10%, mainly due to higher consulting costs. Other expense was $0.1 million versus $0.3 million of other income in Q1 2023.
Cash, liquidity, and obligations: Cash and cash equivalents were $5.4 million at quarter-end, down from $7.0 million at December 30, 2023. Working capital was $11.5 million, down from $14.5 million. No borrowings are reported on the balance sheet. Operating lease liabilities totaled $2.5 million. Purchase commitments were approximately $11.8 million through fiscal 2025, including $9.2 million due within 12 months.
Material developments, outlook, and risks
- Going concern: The company reported substantial doubt about its ability to continue as a going concern for 12 months from the filing date. It expects losses in the next five quarters and says it needs additional capital. Management believes planned spending reductions can alleviate the doubt, but financing is not assured; failure to obtain it could require further spending cuts and harm operations.
- Demand and macroeconomic conditions: Management said customers are extending purchase decision cycles amid economic uncertainty and that a strong U.S. dollar has contributed to demand softness. It cautioned that healthcare capital spending may remain pressured. No quantified revenue or earnings guidance is provided.
- Concentration and related party: Topcon holds a 10% voting interest, distributes products exclusively in certain international territories, and accounted for 32% of quarterly revenue. At March 30, receivables from Topcon were $2.6 million and payables were $0.3 million.
- Liquidity and operating risks: Key disclosed risks include dependence on additional financing, Topcon and international distributors, demand and reimbursement conditions, competition, product quality and supply-chain constraints, and regulatory compliance. International sales were 54.8% of revenue.
- Contingencies and unusual items: Management said ordinary-course legal matters are not expected to have a material adverse effect, while noting litigation can still impose costs and divert resources. No material legal proceeding or off-balance-sheet arrangement is disclosed. No goodwill impairment was recorded.
- Controls: Management concluded disclosure controls and procedures were effective at the reasonable-assurance level as of March 30, 2024; no material change in internal control over financial reporting was reported.
Most important facts for investors to verify
- Whether IRIDEX can raise additional capital on acceptable terms, and how much cash remains available relative to its operating needs.
- Whether spending reductions and any improvement in demand can reduce losses and address the stated going-concern doubt.
- Whether the revenue decline and gross-margin deterioration persist, including the effects of product mix, production volume, and expired royalty patents.
- Topcon’s distribution performance, continued revenue concentration, and collection of the related-party receivable.
- The timing and funding impact of $9.2 million of purchase commitments due within 12 months.